ECM
ITOS

Endurant Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Endurant Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,041
Closed -$411K – 62
2022
Q4 		$411K Buy
+21,041
New +$411K 0.17% 49

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Endurant Capital Management's ITOS Position: Q1 2023 in Review

Endurant Capital Management sold out of iTeos Therapeutics (ITOS) in Q1 2023, closing a stake of 21,041 shares — an estimated $411K sold.

Endurant Capital Management first reported a position in ITOS in Q4 2022 and held it in 1 quarter. The position peaked at $411K in Q4 2022. 153 funds tracked by Wall St. Rank hold ITOS as of Q1 2023.

  • Endurant Capital Management reported no remaining iTeos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 21,041 iTeos Therapeutics shares in Q1 2023, an estimated $411K.
  • Endurant Capital Management first reported a position in iTeos Therapeutics in Q4 2022 and held it in 1 quarter.
  • Endurant Capital Management's iTeos Therapeutics position peaked at $411K in Q4 2022.
  • 153 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.